The authors regret that the Competing Interest in the original paper was not accurate. The correct Competing Interest is as below:
YH received honoraria from Artialis, Bioiberica, Danone, Expanscience, Ibsa, Merck; Pierre Fabre, Synolyne Pharma, Tilman. YH is the founder and chairman of Artialis SA and Synolyne Pharma, two spin-off company of the University of Liège. YH also received unrestricted educational grant from Bioiberica, Expanscience, Royal Canin, Artialis, and Nestle.
The authors would like to apologise for any inconvenience caused.
Article info
Publication history
Published online: August 06, 2014
Identification
Copyright
© 2014 The Authors. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis?MaturitasVol. 78Issue 3
- PreviewChondroitin sulfate and glucosamine sulfate exert beneficial effects on the metabolism of in vitro models of cells derived from synovial joints: chondrocytes, synoviocytes and cells from subchondral bone, all of which are involved in osteoarthritis (OA). They increase type II collagen and proteoglycan synthesis in human articular chondrocytes and are able to reduce the production of some pro-inflammatory mediators and proteases, to reduce the cellular death process, and improve the anabolic/catabolic balance of the extracellular cartilage matrix (ECM).
- Full-Text
- Preview
